Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

Submitted by admin on December 30, 2019 - 10:59am
Source: 
Reuters
News Tags: 
Astellas
Xyphos Biosciences
M&A
Audentes Therapeutics
Headline: 
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
snippet: 

Astellas Pharma Inc (4503.T) has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month.

Do Not Allow Advertisers to Use My Personal information